Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.

Compared to the aggregate P/E ratio of 27.38 in the Pharmaceuticals industry, AstraZeneca Inc. has a higher P/E ratio of ...

AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi ...

With AstraZeneca reported to be looking into moving its listing across the Atlantic, should investors buy the stock ahead of ...

TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.

AstraZeneca Pharma India Share Price Today (11th Jul, 2025): Check AstraZeneca Pharma India Stock Price live NSE/BSE on financialexpress.com. Get AstraZeneca Pharma India today's stock price, 52 ...